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Abstract 
Background: Osteoarthritis is a prevalent disease process that is characterized by degeneration of 
cartilage in weight-bearing joints. This loss of cartilage results in high levels of pain, joint stiffness, loss of 
range of motion and function, and psychological distress. Current osteoarthritis treatment focuses on 
reduction of pain and swelling and improvement of quality of life for the patients. Recently, mesenchymal 
stem cells have been of interest in this disease process due to their self-renewal, multipotent 
differentiation, and immunomodulatory properties. Can mesenchymal stem cell injections or implantation 
in patients with osteoarthritis of the knee improve level of function and magnetic resonance imaging 
results? 
Methods: An exhaustive search of available medical literature using MEDLINE-Ovid, CINAHL, and Web of 
Science was conducted using the key words “mesenchymal stem cell transplantation” and “osteoarthritis, 
knee”. The results were screened with eligibility criteria. The remaining articles were evaluated and 
assessed for quality using GRADE. 
Results: Two studies met inclusion and exclusion criteria and were included in this systematic review. One 
prospective cohort study looked at 20 patients with osteoarthritis of the knee and performed 
mesenchymal stem cell implantation. The results showed overall improvement in level of function and 
magnetic resonance imaging (MRI) results. One therapeutic case series looked at 25 patients with 
osteoarthritis of the knee and performed mesenchymal stem cell injections. Although seven patients 
were lost to follow-up, results showed overall improvement in pain, level of function, and MRI results. 
Conclusion: Mesenchymal stem cell implantation or injections have been found to improve level of 
function and MRI results at two years after the initial procedure. However, there is not sufficient quality 
evidence to show that this treatment option should be implemented into standard of care for patients 
with osteoarthritis. While study results are promising, further research with larger study sizes, variable 
techniques, and longer follow-up are needed to validate this treatment and determine at what point in the 
osteoarthritis disease process it should be utilized. 
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Abstract   
 
Background: Osteoarthritis is a prevalent disease process that is characterized by 
degeneration of cartilage in weight-bearing joints.  This loss of cartilage results in high 
levels of pain, joint stiffness, loss of range of motion and function, and psychological 
distress.  Current osteoarthritis treatment focuses on reduction of pain and swelling and 
improvement of quality of life for the patients.  Recently, mesenchymal stem cells have 
been of interest in this disease process due to their self-renewal, multipotent 
differentiation, and immunomodulatory properties. Can mesenchymal stem cell injections 
or implantation in patients with osteoarthritis of the knee improve level of function and 
magnetic resonance imaging results? 
 
Methods:  An exhaustive search of available medical literature using MEDLINE-Ovid, 
CINAHL, and Web of Science was conducted using the key words “mesenchymal stem 
cell transplantation” and “osteoarthritis, knee”.  The results were screened with eligibility 
criteria.  The remaining articles were evaluated and assessed for quality using GRADE. 
 
Results:  Two studies met inclusion and exclusion criteria and were included in this 
systematic review.  One prospective cohort study looked at 20 patients with osteoarthritis 
of the knee and performed mesenchymal stem cell implantation.  The results showed 
overall improvement in level of function and magnetic resonance imaging (MRI) results.  
One therapeutic case series looked at 25 patients with osteoarthritis of the knee and 
performed mesenchymal stem cell injections.  Although seven patients were lost to 
follow-up, results showed overall improvement in pain, level of function, and MRI 
results. 
 
Conclusion:  Mesenchymal stem cell implantation or injections have been found to 
improve level of function and MRI results at two years after the initial procedure.  
However, there is not sufficient quality evidence to show that this treatment option 
should be implemented into standard of care for patients with osteoarthritis.  While study 
results are promising, further research with larger study sizes, variable techniques, and 
longer follow-up are needed to validate this treatment and determine at what point in the 
osteoarthritis disease process it should be utilized. 
 
Keywords: “Mesenchymal stem cell transplantation” and “knee osteoarthritis” 
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Injection and Implantation of Mesenchymal Stem Cells 
for Improvement of Osteoarthritis in Knees 
BACKGROUND 
 Osteoarthritis (OA) is the most common cause of knee pain in older adults, and 
over 75% of adults ages 65 and older have radiographic evidence of this disease.  OA is a 
disease process that involves the degeneration of cartilage and excessive bone growth at 
weight bearing joints.  The degeneration of cartilage at joint surfaces results in bony 
surfaces rubbing together that, in turn, causes a deep, aching pain. Not only does OA 
cause pain in joints, it can also result in many other physical issues including stiffness 
after periods of inactivity, limited range of motion, and a decreased level of function.1  In 
addition, OA can have negative effects on an individual’s self-assessed health2 and can 
result in psychological distress including depression, anxiety, and overall decreased 
emotional well-being.3,4  Despite the extreme effect OA can have on an individual’s life 
and general health, current and non-surgical treatments only focus on reducing pain and 
inflammation, not regenerating the cartilage that has been lost in the disease process. 
 The current managment of OA includes both nonpharmacologic and 
pharmacologic treatments that focus on reducing pain, improving level of function, and 
improving the quality of life for individuals suffering from OA.5  Nonpharmacologic 
treatments include avoiding activities that cause excessive impact on the joint, focusing 
on weight loss, physical therapy, and use of canes or walkers.1  Pharmacologic therapy 
includes acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), intra-articular 
injections of corticosteroids, intra-articular injections of hyaluronic acid, and 
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glucosamine and chondroitin sulfate supplements.  The final step in therapy is a total joint 
replacement, which is delayed as long as possible by way of the these metho.1 
 Recently, mesenchymal stem cells (MSCs) have been receiving attention in their 
potential use in the treatment of OA.  Certain characteristics of these cells such as self-
renewal, multipotent differentiation, and immunomodulatory properties may allow them 
to be used in the treatment and regeneration of cartilage lesions.6  In addition to these 
properties, MSCs are retrieved from the same patient that will be receiving the cells.  
This is an important factor because it reduces controversy of embryonic stem cells, and 
there is no concern regarding rejection of the cells or disease transmission.7  While the 
use of MSCs in the treatment of OA is not currently considered standard of care, there is 
potential that this treatment method may reverse the disease process of OA and improve 
level of function and MRI results.  Can mesenchymal stem cell injections or implantation 
in patients with osteoarthritis of the knee improve level of function and magnetic 
resonance imaging results? 
METHODS 
An exhaustive online literature search using MEDLINE-Ovid, CINAHL, and 
Web of Science was conducted.  The following keywords were used: “mesenchymal stem 
cell transplantation” and “osteoarthritis, knee”.  Duplicates were removed and eligibility 
criteria were applied to the search results.  Inclusion criteria were: studies with 
osteoarthritis of the knee, using injection or implantation of mesenchymal stem cells, and 
that assessed level of function and MRI results at 2 years or more after the procedure. 
Exclusion criteria were: non-English studies, non-human studies, studies published 
before 2011, studies with sample size smaller than 10, studies with follow-up less than 2 
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years, studies using stem cells not derived from the infrapatellar fat pad or adipose tissue, 
studies that used microfractures, abrasion, osteotomies procedures, or hyaluronic acid 
injections, and studies that used second-look arthroscopic data instead of MRI findings. 
Applicable articles were assessed for quality using the Grading of Recommendations, 
Assessment, Development, and Evaluation (GRADE).8 
RESULTS 
 An initial search of MEDLINE-Ovid using the keywords previously mentioned 
and with the criteria of English and human-only studies yielded 36 articles.  Of these, one 
article9 met the eligibility criteria.  It is important to mention that one of the other 
articles10 revealed in the initial search was based on the same study; however, this article 
was the one year follow-up to the study9 and only evaluated for safety of the injections, 
reduction of pain, and increased level of function.  This article10 was referenced for 
procedural methods and one year follow-up findings, but was not included in the 
systematic review due to the exclusion criteria of less than 2 years follow-up and no MRI 
evaluation.  An initial search of CINAHL with the keywords yielded 3 articles.  Of these, 
2 were duplicates and the third did not meet eligibility criteria.  An initial search of Web 
of Science with the keywords yielded 87 articles.  Of these, 14 articles were duplicates 
and 72 articles did not meet eligibility criteria. One article11 did meet eligibility criteria.  
In total, two articles were evaluated for this systematic review (Table 1). 
Kim et al (2015) 
 This 2 year prospective cohort study11 was conducted to evaluate clinical 
outcomes and MRI results, and to determine an association between clinical and MRI 
outcomes, after MSC implantation with a fibrin glue scaffold in patients with OA of the 
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knee.  Another aim of the study was to use MRI evaluation to assess for cartilage 
regeneration after MSC implantation with a fibrin glue scaffold.  Patients were included 
in the study if they had OA of the knee with isolated articular cartilage lesions (Kellgren-
Lawrence12 grades 1-2) and were experiencing continued symptoms of knee joint pain 
and/or functional limitations despite three or more months of nonsurgical treatments (ie, 
rest, physical therapy, and NSAIDs).  Exclusion criteria included a history of surgical 
treatments, multiple cartilage lesions, knee instability, varus or valgus malalignment of 5⁰ 
or more of the knee joint, metabolic arthritis, joint infections, or large meniscal tears.  
The study included 11 men and 9 women, with a mean age of 57.9 years (SD, 5.9; range, 
48-69) and a mean preoperative body mass index (BMI) of 26.6 kg/m2 (SD, 3.2; range, 
22.2-31.2).   The mean MRI follow-up was 24.2 months after surgery (range, 18-29 
months), and overall outcome follow-up occurred at a mean of 27.9 months (SD, 3.2; 
ranger 24-34).11 
 MSC preparation began by collecting 140cc of buttock adipose tissue from each 
patient through a liposuction procedure one day before the arthroscopic surgery and MSC 
implantation.  Of the 140cc of adipose tissue collected during the operation, the 120cc 
intended to be used for implantation was placed in phosphate-buffered solution and then 
transferred to the laboratory in a sterile box.  The 20cc intended to be used for analysis of 
the cells and confirm the multilineage differentiation, were processed identically to the 
120cc aforementioned. These cells were then isolated and prepared for injection by 
methods described in the article.11 
 Prior to implantation of MSCs, all patients underwent surgical debridement of 
unstable and damaged cartilage.  For MSC implantation, a commercially acquired fibrin 
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glue product kit was used as a scaffold.  The fibrin glue product was supplied and 
administered as 2 separate solutions in 2 separate syringes.  One solution was lyophilized 
human plasma fibrinogen (71.5-126.5 mg/mL) dissolved in 1 mL of aprotinin solution 
and the other was thrombin (4.9-11.1mg/mL) dissolved in 1mL calcium chloride solution 
(13.9-15.6 mg/mL).  When these two products are combined in a 1:1 ratio by the means 
of the 2 syringes on the knee cartilage, they form a gel.  In order to incorporate the MSCs 
into the fibrin scaffold, the stromal vascular fraction cells containing MSCs were 
combined with the thrombin solution in a 1:1 ratio.  This mixture was then combined 
with the fibrinogen solution in a 1:1 solution onto the surface of the cartilage lesions by 
way of the syringes under arthroscopic guidance, and then manipulated by the probe to 
coat the surface of the cartilage lesion.  Before the implantation, arthroscopic fluid was 
extracted.11 
 Patient movement and activity was limited for 4 weeks after the implantation 
procedure.  For the first 2 weeks, the knee was immobilized in a knee brace.  During the 
following 2 weeks (weeks 2-4 after the procedure), the patients began range-of-motion 
exercises and partial weight bearing.  At 4 weeks after the procedure, patients were 
allowed to begin full weight-bearing activities, and at 3 months, full return to sports, 
high-impact activities, and recreational activities was allowed as tolerated.11 
Preoperative and postoperative level of function and sports activity was evaluated 
by utilizing the International Knee Documentation Committee (IKDC) score13 and the 
Tegner activity scale14, while preoperative and postoperative MRI evaluations were 
performed according to the MRI Osteoarthritis Knee Score (MOAKS).15  The MOAKS 
system encompasses 7 independent criteria, 1 of which (articular cartilage grading 
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system) was used in this study.11  The articular cartilage grading system scores the 
cartilage damage on 2 separate aspects: size of the lesion in surface area and size of the 
lesion in depth.  The preoperative and postoperative MRI studies were evaluated 
according to the MOAKS system by a musculoskeletal-trained radiologist who was not 
informed of the intentions of the study and who was not involved in the care of the 
patients.  In additions to MOAKS grading, a postoperative MRI evaluation was also 
performed according to Magnetic Resonance Observation of Cartilage Repair Tissue 
(MOCART) score.16,11 
At the mean follow-up of 27.9 months (range, 24-34 months), the IKDC score 
improved from a mean of 38.7 (SD, 7.0) preoperatively to a mean of 67.3 (SD, 11.6) 
(P<0.001), and the Tegner activity scale score improved from a mean of 2.5 (SD, 0.9) 
preoperatively to a mean of 3.9 (SD, 0.7) (P<0.001).  In regards to patient satisfaction, 
50% reported excellent, 33.3% reported good, 12.5% reported as fair, and 4.2% reported 
as poor.11 
Prior to MSC implantation, 21 lesions (87.5%) were grade 2 or 3 according to 
MOAKS system grading for surface area of cartilage loss, and after implantation, 5 
lesions (20.8%) were grade 2 and 3.  According to the MOAKS system grading for full-
thickness cartilage loss, 23 lesions (95.9%) were grade 2 or 3 prior to implantation, and 
after implantation, 5 (20.8%) were grade 2 or 3.  Both of these findings were statistically 
significant (P<0.001).  The mean MOCART score was 69.8 (SD, 14.3) at final follow 
up.11 
In addition to the improvement in IKDC score, Tegner activity scale, and cartilage 
lesion grades according to the MOAKS system, it was also found that a decrease in the 
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grades for full-thickness cartilage loss and a decrease in the grades for the size of 
cartilage-loss area was associated with an increase in the IKDC score and Tegner activity 
scale (P<0.05 for all).  It was also determined that various factors (age, sex, BMI, and 
size and location of cartilage lesion) did not independently affect clinical outcomes.11 
There were a few limitations to this study that were noted by the researchers.  
First, there was a small patient population size and short follow-up period.  Second, an 
arthroscopic debridement procedure was performed at the same time as the implantation, 
so the efficacy of MSC implantation alone is unknown.  Additionally, a fibrin glue 
scaffold was used with MSC in the study, so the efficacy of MSC implantation without 
this scaffold is unknown.  Third, only one observer was used to evaluate the MRI results, 
so it was not possible to determine inter-observer variability.  Fourth, the optimal number 
of MSCs that should be used in implantation is still unknown and it has not been 
determined if multiple injections of MSCs would be more beneficial than just one.11 
Koh et al (2013) 
 This therapeutic case series9 was conducted to evaluate the clinical and MRI 
results of individuals who received injections of MSCs for the treatment of OA 2 years 
prior.  In this study, the records of patients who had undergone MSC injections in the 
primary study10 were retrospectively reviewed, and MRI studies and evaluations were 
performed at the 2-year follow-up.  The primary, 1-year follow-up study10 was conducted 
to evaluate the safety of MSC injections and to assess whether these injections improved 
level of pain and function.  Patients were included in the study if they were 30 years of 
age or older and had idiopathic or secondary knee OA (Kellgren-Lawrence12 grade 3 in 
multiple compartments or 4 in one compartment).  Exclusion criteria included Kellgren-
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Lawrence12 grade 4 in 2 or more compartments, inflammatory or post-infectious arthritis, 
previous arthroscopic treatment, varus or valgus deformity of 5⁰ or more, previous major 
knee trauma, intra-articular corticosteroid injection in the last 3 months, serious medical 
illness, major neurological defects, large meniscal tears, or were unable to provide 
consent.  The original study10 included 8 men and 17 women with a mean age of 54.1 
(range, 34-69); however, in the 2-year follow-up study9 seven patients were lost to 
follow-up.  Two of these patients did not want to visit the hospital and 5 of the patients 
declined MRI examination; therefore, only 18 patients (6 men and 12 women with a 
mean age of 54.6 [range, 41-69]) were examined completely at the 2-year follow-up.9 
 Starting at 1 week prior to the surgical procedures (all of which were performed 
on the same day and by a single surgeon [Y-G.K.]), patients were directed to refrain from 
taking NSAIDs.  To begin the procedural process, patients received spinal anesthesia and 
underwent an arthroscopic procedure in which the medial, lateral, and patellofemoral 
joint compartments were evaluated and graded according to the International Cartilage 
Repair Society (ICRS) Cartilage Injury Evaluation Package.17 After grading was 
complete, the compartment was irrigated with at least 1L of saline solution and a 
treatment procedure was performed (synovectomy, debridement, or excision of 
degenerative tears of the menisci, fragments of articular cartilage, chondral flaps, or 
osteophytes that prevent full extension).9  Immediately after the procedure, infrapatellar 
fat pad (mean weight 9.1g; range, 6.4-13.1g) and adipose synovium were harvested from 
the knee of the patient.  MSCs were then derived from the fat pad and counted with a 
hemocytometer.  Platelet-rich plasma (PRP) was a second component that was necessary 
to mix with the harvested MSCs.  In order to prepare and isolate PRP, 60mL of venous 
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blood was collected from each patient and was placed in a bag with 4mL sodium citrate.  
The samples were then put through the centrifuge twice.  The first time, the erythrocytes 
were separated out, and the second time the platelets were concentrated to yield 6mL 
PRP.9  The sample was then divided into 2 units of 3mL (mean of 1.28x106 platelets per 
microliter).  Before each injection of 3mL PRP, the PRP was mixed with calcium 
chloride to activate the platelets. The process of preparing PRP and isolating MSCs took 
about 3 to 4 hours, and was completed on the same days as the surgical procedures.9 
 MSC injection was the next step in the procedural process.  To begin, the 
injection site (lateral upper pole of the patella) was dressed under antiseptic techniques 
and aspiration for hemarthrosis was performed.  Next, the MSC solution (mean of 
1.18x106 stem cells [range, 0.3x106 to 2.7x106 stem cells] mixed with 3mL platelet-rich 
plasma [PRP]) was injected by way of a 22-gauge needle.  After the injection, the 
patients were encouraged to move their knee, apply ice after discharge from the hospital, 
and no walking restrictions were placed on the patients.  Two more injections consisting 
of only 3mL of PRP (no MSCs) were administered in an outpatient setting at 7 and 14 
days after the procedure.  Return to sports and recreational activities was allowed as 
tolerated.  No form of formal rehabilitation was used, and no analgesics, anti-
inflammatory drugs, or immunosuppressant therapy were administered or allowed.9 
 Each patient was evaluated preoperatively, at 3 months, at 12 months, and at a 
mean 24.3 months (range, 24 to 26 months) according to the Western Ontario and 
McMaster Universities Osteoarthritis Index (WOMAC),18 the Lysholm score,19 and the 
visual analog scale (VAS).  These scores and scales were used to assess for pain and level 
of function.  For evaluation of preoperative and 2-year follow-up MRI results, 2 
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musculoskeletal radiologists (S-W.L. and S-H.P.) independently scored the MRIs 
according to the whole-organ MRI score (WORMS).20,9 
 The WOMAC scores were reported as 49.9 preoperatively, 38.3 at 1-year follow-
up, and 30.3 at the final 2-year follow-up.  When the preoperative scores were compared 
to the 2-year follow-up scores, they were found to be statistically significant (P= <0.001).  
Additionally, it was found that the WOMAC score also improved in relation to the 
number of MSCs that were injected (P=0.011); therefore, treatment became more 
effective as more MSCs were injected.  Lysholm scores were reported at a mean of 40.1 
preoperatively and increased to a mean of 73.4 at the final 2-year follow-up.  Similarly, 
the mean VAS score was reported at 4.8 preoperatively and decreased to 2.0 at the final 
two-year follow-up.  Both the change in the Lysholm score and the VAS score were 
found to be statistically significant (P<0.001 and P=0.005, respectively).9 
 Similarly as to what was found in the WOMAC score, Lysholm score, and VAS 
score, WORMS scores improved from a preoperative score of 60.0 to a 2-year follow-up 
score of 48.3, which was determined to be statistically significant (P<0.001).  
Furthermore, greater improvements in the WORMS score was seen in the patients who 
had received a greater number of MSCs in the injection (P=0.002).9 
 There were a few limitations to this study.  First, in the one-year follow-up 
article10 there was a control group who only received PRP for all three injections.  
Although the results from this group were evaluated and reported in the first article10 
there was no mention of this control group in the two-year follow-up paper.9  Second, 
procedures were performed at the same time as the MSC injection, which may have had 
an impact on the outcome.  Third, the results of the study showed that patients 
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experienced better outcomes when they received a larger number of MSCs, but the 
optimal number is unknown.  Fourth, only a single injection of MSCs was given, so it is 
not known if multiple injections would be beneficial.  Fifth, the MSC injections were 
prepared with PRP; therefore, it is not known how the MSCs would affect the patients if 
given alone, or if the benefit seen in this study was from the PRP and not the MSCs.  
Sixth, 7 patients (about 30%) were lost to follow-up.9,10 
DISCUSSION 
 OA involves the degeneration of cartilage which results in pain and can be 
debilitating.  All of the current treatments focus on managing the pain and swelling, and 
trying to improve quality of life for the patients.  None of these treatment options focus 
on reversing the damage that has been done by the disease process.  This systematic 
review was performed to determine if mesenchymal stem cell injections or implantation 
in patients with osteoarthritis of the knee can improve level of function and magnetic 
resonance imaging results. 
 Both of the studies9,11 that were evaluated in this systematic review found that the 
use of MSCs in the knees of patients with OA improved level of function and MRI 
results.  Although the two studies9,11 used different scales to evaluate level of function, 
the data in both studies supported the fact that MSCs improved the level of function in 
patients with OA of the knee at 2 years after the procedure.  Similarly,  the studies 
utilized different scales to analyze MRI results before and 2 years after the procedure, but 
both found significant improvement (P<0.001).  Furthermore, the second study9 used the 
VAS scale to determine that MSC injections also helped with pain level.  Due to the 
results of these studies, implantation or injection of MSCs have a promising role in the 
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future for cartilage regeneration in OA knees and improving level of function in these 
patients.   
 There were many issues in variability between the two studies that were evaluated 
in the systematic review.  First, the first study11 used an implantation method of MSCs 
combined with a fibrin scaffold with two weeks of knee immobilization and gradual 
return to weight bearing, while the second study9 used an injection method of MSCs 
combined with PRP with encouraged immediate motion and return to activity as 
tolerated.  However, both of these techniques resulted in the delivery of MSCs onto the 
surface of the cartilage lesion along with a substance (fibrin matrix or PRP) that would 
form a gel in the knee.  Second, the two studies9,11 used different scales to evaluate for 
level of function (IKDC/Tegner activity scale vs. WOMAC/Lysholm) and to evaluate the 
MRI results (MOAKS/MOCART vs. WORMS).  Although the scales varied between the 
two studies, they both used validated scoring techniques that adequately addressed the 
level of function and MRI findings of each patient before and after the procedure.  Third, 
the second study9 evaluated for pain level before and after the procedure, while the first 
study11 did not focus on the aspect of pain. 
 There were a few important limitations in both of these studies that resulted in a 
downgrade in the quality of the articles and the outcomes according to the GRADE 
system (Table 1).  One main issue was the small sample size in both of these studies.  The 
first study11 only consisted of 20 patients (24 knees), while the second study9 consisted of 
25 patients.  However, in the second study, 7 patients were lost to follow-up, so the final 
study size was 18.  A second limitation was the use of surgical procedures at the same 
time as the injection or implantation along with the use of a fibrin scaffold11 or a PRP 
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injection.9  Due to these concomitant procedures, it is unclear whether the procedures 
influenced the improvement, or whether the MSCs were responsible.  Since both of the 
studies included in this systematic review were observational studies, they both started 
out with a Low quality.  Furthermore, due to the reasons aforementioned, both of the 
studies and outcomes were downgraded to Very Low quality.  Worth noting is the 
observation that the second study9 demonstrated a dose-response gradient between the 
number of stem cells and outcomes. 
 While these two articles found that the implantation or injection of MSCs improve 
level of function and MRI results in individuals with OA of the knees, it is not certain if 
this treatment should be applied to all individuals with OA of the knees and where this 
treatment would fit into therapy.  Future research is needed to confirm the effect of this 
treatment and when it should be utilized.  Further research should include studies with a 
larger sample size, studies that use multiple injections of MSCs, studies that only use 
MSCs, studies that only use PRP, studies that only use fibrin scaffold, studies that use 
dose escalating MSC injections, and studies that have a longer follow-up period to 
determine if this procedure is definitive. It would also be beneficial to perform studies 
that analyze whether MSC injections or implantations are more beneficial than the 
standard therapies, and if MSCs delay or eliminate the need for a total knee replacement. 
CONCLUSION 
Current treatment of OA focuses only on managing the dull aching pain and 
inflammation that decreases function, not halting or reversing the cause of the pain.  This 
systematic review was conducted to determine if MSC injections or implantation in 
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patients with OA of the knee can improve level of function and MRI results.  Two studies 
were analyzed, and both found that the implantation or injection of MSCs into the knee of 
individuals with OA aids in cartilage regeneration which, in turn, improves level of 
function and MRI results.  Although the results of these two studies are promising, due to 
the very low level of quality of the evidence, it cannot be determined at this time if this 
treatment method should be implemented into standard of care and how it would fit into 
OA treatment.  Further research needs to be done.  Despite the need for further areas of 
research, research thus far has shown promising results in the ability of MSC injections 
and implantations in OA knees to halt and reverse the damage and pain of OA, and have 
the possibility to delay or eliminate the knee for total knee replacement surgery. 
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Table 1: Quality Assessment of Reviewed Articles 
Outcome 
Number 
of 
studies 
Study 
Designs 
Downgrade Criteria 
Upgrade 
Criteria 
Quality 
Limitations Indirectness Inconsistency Imprecision 
Publication 
bias 
MRI Results 2 Case 
Control,  
Cohort 
Seriousa,b Not Serious Not Seriousc Seriousd Unlikely Dose-Response 
Gradiente 
Very Low 
Level of Function 2 Case 
Control, 
Cohort 
Seriousa,b Not Serious Not Serious c Seriousd Unlikely Dose-Response 
Gradiente 
Very Low 
aKoh et9 al lacked follow-up MRI results for the control group. 
b Both studies9,11 did arthroscopic debridement at the time of the procedure and mixed MSC with another medium (PRP or fibrin scaffold) which may 
have influenced outcomes.  
c Although the two studies9,11 used different intervention types (injection and transplantation) and different rating scales for level of function and MRI 
evaluation, they both used mesenchymal stem cells and outcomes were similar. 
d Both of the studies9,11 have a small sample size. 
eKoh et al9 showed a dose-response gradient between number of MSCs and level of function/MRI results and Kim et al11 showed an increasing 
correlation between MRI and level of function. 
 
